<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bionano Genomics Inc — News on 6ix</title>
    <link>https://6ix.com/company/bionano-genomics-inc</link>
    <description>Latest news and press releases for Bionano Genomics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bionano-genomics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354e9978dffbe2df0e66db.webp</url>
      <title>Bionano Genomics Inc</title>
      <link>https://6ix.com/company/bionano-genomics-inc</link>
    </image>
    <item>
      <title>Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-to-report-first-quarter-2026-financial-results-and-host-a-conference-call-webcast-on-may-13-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-to-report-first-quarter-2026-financial-results-and-host-a-conference-call-webcast-on-may-13-2026</guid>
      <pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
      <description>SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2026 and to highlight recent corporate progress. Conference Call &amp; Webcast Details Date:Wednesday, May 13th, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may access a live w</description>
    </item>
    <item>
      <title>Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-from-johns-hopkins-and-md-anderson-showing-that-ogm-can-outperform-traditional-methods-in-analysis-of-multiple-myeloma-47</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-from-johns-hopkins-and-md-anderson-showing-that-ogm-can-outperform-traditional-methods-in-analysis-of-multiple-myeloma-47</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology</description>
    </item>
    <item>
      <title>Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-fourth-quarter-and-full-year-2025-results-and-provides-revenue-outlook-for-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-fourth-quarter-and-full-year-2025-results-and-provides-revenue-outlook-for-2026</guid>
      <pubDate>Mon, 23 Mar 2026 20:05:00 GMT</pubDate>
      <description>Conference call today, March 23, 2026, at 4:30 PM ETSAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. &quot;2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see co</description>
    </item>
    <item>
      <title>Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-two-fold-increase-in-ogm-studies-presented-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-two-fold-increase-in-ogm-studies-presented-at-the-2026-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the 2026 American College of Medical Genetics and Genomics</description>
    </item>
    <item>
      <title>Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-a-conference-call-webcast-on-march-23-2026-4</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-to-report-fourth-quarter-and-full-year-2025-financial-results-and-host-a-conference-call-webcast-on-march-23-2026-4</guid>
      <pubDate>Mon, 09 Mar 2026 20:05:00 GMT</pubDate>
      <description>SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress. Conference Call &amp; Webcast Details Date:Monday, March 23rd, 2026Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:Registration – Click here Participants may ac</description>
    </item>
    <item>
      <title>Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-symposium-2026-concluded-with-9-speakers-describing-the-breadth-of-bionano-solutions-and-their-potential-for-use-on-a-large-scale</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-symposium-2026-concluded-with-9-speakers-describing-the-breadth-of-bionano-solutions-and-their-potential-for-use-on-a-large-scale</guid>
      <pubDate>Fri, 27 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software.</description>
    </item>
    <item>
      <title>10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/10-presentations-on-day-3-of-bionano-symposium-2026-showcase-ogms-utility-in-unraveling-the-complex-puzzles-of-constitutional-genetic-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/10-presentations-on-day-3-of-bionano-symposium-2026-showcase-ogms-utility-in-unraveling-the-complex-puzzles-of-constitutional-genetic-disorders</guid>
      <pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to the cytogenetics and molecular pathology teams inve</description>
    </item>
    <item>
      <title>11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell &amp; Gene Therapy</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/11-presentations-on-day-2-of-bionano-symposium-2026-showcase-expanding-impact-of-optical-genome-mapping-across-oncology-and-cell-and-gene-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/11-presentations-on-day-2-of-bionano-symposium-2026-showcase-expanding-impact-of-optical-genome-mapping-across-oncology-and-cell-and-gene-therapy</guid>
      <pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing Applications with Optical Genome Mapping (OGM). The session revealed how OGM can offer a new standard for detecting and characterizing structural variants (SVs) across cancer, including its unprecedented resolution in rare and heterogeneous cancers. Presentations also described how OGM is i</description>
    </item>
    <item>
      <title>9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/9-presentations-kick-off-day-1-of-the-bionano-symposium-2026-covering-advances-in-optical-genome-mapping-for-hematologic-malignancies</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/9-presentations-kick-off-day-1-of-the-bionano-symposium-2026-covering-advances-in-optical-genome-mapping-for-hematologic-malignancies</guid>
      <pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical st</description>
    </item>
    <item>
      <title>Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-bionano-symposium-2026-140500585</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-bionano-symposium-2026-140500585</guid>
      <pubDate>Mon, 09 Feb 2026 14:05:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform for researchers to present cutting-edge findings and share insights into emerging applications of OGM technology. Join leading scientists from around the world as they highlight breakthroughs in OGM from February 23-26, 2026. The four-day event will feat</description>
    </item>
    <item>
      <title>Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-sanford-burnham-130000438</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-sanford-burnham-130000438</guid>
      <pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods &amp; Clinical Development, describing the application of optical genome mapping (OGM) to detect genomic alterations introduced by different gene editing technologies, including transposons, lentiviral transduction, and CRISPR-Cas9-mediated locus insertion. The results suggest that OGM could be a valuable tool for quality control (QC) of cell-lin</description>
    </item>
    <item>
      <title>Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-preliminary-fourth-quarter-130000109</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-preliminary-fourth-quarter-130000109</guid>
      <pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping (OGM) solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of</description>
    </item>
    <item>
      <title>Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-recaps-advances-optical-genome-130000072</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-recaps-advances-optical-genome-130000072</guid>
      <pubDate>Thu, 11 Dec 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the detection of structural variants (SVs) with greater clarity and sensitivity than traditional cytogenetic and molecular techniques. Through platform presentations and poster sessions, multiple researchers emp</description>
    </item>
    <item>
      <title>Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/final-2026-clinical-lab-fee-130000461</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/final-2026-clinical-lab-fee-130000461</guid>
      <pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare &amp; Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the Category I Current Procedural Terminology (CPT®) code 81195. Thi</description>
    </item>
    <item>
      <title>Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-third-quarter-2025-210100573</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-reports-third-quarter-2025-210100573</guid>
      <pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
      <description>Conference call today, November 13, 2025, at 4:30 PM ETSAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in the third quarter and year-to-date validates this strategic shift a</description>
    </item>
    <item>
      <title>Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-showing-ogm-130000488</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-announces-publication-showing-ogm-130000488</guid>
      <pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of targeted RNA-sequencing (RNA-seq) panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Det</description>
    </item>
    <item>
      <title>Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-report-third-quarter-2025-200500627</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-report-third-quarter-2025-200500627</guid>
      <pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call &amp; Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Partic</description>
    </item>
    <item>
      <title>Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-highlights-global-momentum-behind-120000589</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-highlights-global-momentum-behind-120000589</guid>
      <pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the potential for an expanding role of optical genome mapping (OGM) in genetic disease research. Multiple presentations and posters showcased its effectiveness in detecting structural variants (SVs) associated with a range of genetic conditions, including facioscapulohumeral muscular d</description>
    </item>
    <item>
      <title>Bionano to Participate in the H.C. Wainwright @ Home Event</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-participate-h-c-wainwright-120000542</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-participate-h-c-wainwright-120000542</guid>
      <pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025. Conference &amp; Webcast Details Date:October 15, 2025Time:10:00 a.m. to 11:00 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the</description>
    </item>
    <item>
      <title>Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering</title>
      <link>https://6ix.com/company/bionano-genomics-inc/news/bionano-genomics-inc-announces-closing-210000422</link>
      <guid isPermaLink="true">https://6ix.com/company/bionano-genomics-inc/news/bionano-genomics-inc-announces-closing-210000422</guid>
      <pubDate>Wed, 17 Sep 2025 21:00:00 GMT</pubDate>
      <description>SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, co</description>
    </item>
  </channel>
</rss>